Fewer than one in 10 people who could benefit from weight-loss injections such as Wegovy are able to get them, caution the WHO as it publishes its initial advice on the medications.
With in excess of 1,000,000,000 people worldwide now classified as obese, it is urging increased and just availability to GLP-1 medication.
Based on projections, more than two billion could be obese by 2030 unless action is taken.
"Our latest guidelines acknowledges that obesity is a chronic disease that can be managed with comprehensive and continuous support," remarked its chief Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and distribution challenges are significant hurdles to universal access to the jabs that can aid individuals in losing significant body mass, explains the body.
Weight-Loss Drug Scarcity
Even in the present most favorable scenario, the manufacturing of GLP-1 therapies might only reach about 100 million people – under 10% of eligible patients, per the WHO.
The advice calls on countries and companies to expand access, via approaches like licensing agreements.
The intellectual property rights on the active ingredient – the core ingredient of the drug Wegovy – is set to lapse in several nations in 2026.
How Obesity Jabs Function
GLP-1 drugs replicate a natural hormone to reduce digestion speed, suppress the appetite and increase the sense of being full so individuals eat less.
Patients usually see weight reduction within a few weeks of commencing the regular doses.
Evidence points to users may regain a significant portion within a year of discontinuing the drug, when their typical hunger resume.
Being carrying excess weight raises your likelihood for experiencing diseases, such as diabetes, cardiovascular issues, stroke, and specific cancers.
Obesity concerns people in every country and was responsible for 3.7 million fatalities worldwide in 2024, per the WHO.
